Sign In
Buy PIRS
$13.60
+0 (+0%)
At Close: Mar 12, 2025
PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today
10:42am, Wednesday, 26'th May 2021
Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. The post PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Toda
Are Options Traders Betting on a Big Move in Pieris (PIRS) Stock?
09:46am, Wednesday, 26'th May 2021
Investors need to pay close attention to Pieris (PIRS) stock based on the movements in the options market lately.
Best Biotech Penny Stocks in June 2021? Check These 4 Out
09:04am, Wednesday, 26'th May 2021
Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?
PIRS Stock Price: 103.24% Increase Explanation
06:22am, Wednesday, 26'th May 2021
The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by 103.24% yesterday. This is why it happened.
Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billion
01:32pm, Tuesday, 25'th May 2021
Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboratio
Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021
11:47am, Tuesday, 25'th May 2021
Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?
What's Going On With Pieris Pharmaceuticals Stock Today?
11:43am, Tuesday, 25'th May 2021
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are trading higher by 57% at $2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. Pieris Pharmaceuticals is a
PIRS Stock Price: Over 30% Increase Pre-Market Explanation
08:46am, Tuesday, 25'th May 2021
The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by over 30% pre-market. This is why it happened.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q1 2021 Results - Earnings Call Transcript
02:04pm, Monday, 17'th May 2021
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q1 2021 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Monday, 17'th May 2021
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 58.82% and 141.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Pieris Pharmaceuticals: Q1 Earnings Insights
07:34am, Monday, 17'th May 2021
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.07), which beat
Earnings Preview: Pieris Pharmaceuticals
10:29am, Friday, 14'th May 2021
On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
PIRS Stock: Over 5% Increase Pre-Market Explanation
08:26am, Monday, 26'th Apr 2021
The stock price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) increased by over 5% pre-market. This is why it happened.
Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the progra
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in
